Response to influenza virus vaccination in patients immunocompromised due to chemotherapy

Response to influenza virus vaccination in patients immunocompromised due to chemotherapy - Rifluvac

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON33424

Enrollment

385

Registered

2009-07-27

Start date

2009-10-08

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer. Mamma carcinoma

Interventions

The influenza virus vaccine is given in the period October/November 2009

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1.Patients with mamma carcinoma treated with FEC-containing triweekly chemotherapy at moment of vaccination 2.Patients with heart failure and therefore having an indication for the influenza vaccination 3.Age >= 18 years 4.Signing of informed consent

Exclusion criteria

Exclusion criteria: 1.Fever at time of vaccination defined as a temperature of >= 38.5 °C. 2.Previous/known allergic reaction to any of the components of the vaccines given, for example hypersensitivity to egg protein 3.Thrombocytopenia (defined as

Design outcomes

Primary

Measure	Time frame
adequate rise in antibody titre against the influenza virus	—

Secondary

Measure	Time frame
·Antibody titres against the influenza virus before and after vaccination	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)